October 2024. The success of the Munich biotech hub lured Bavarian politics and its management arms into self-complacency. However, the wind has changed: Broad availability of artificial Intelligence (AI), cautious investors, competitive biotech hubs outside Bavaria – the old boys’ network became patchy. BioM is going to be re-imagined as cluster development strives to connect to new actors and thinks about alternative investments opportunities, but there are some pitfalls.
B2Bioworld enquired into “System Domdey”, changing relations to Fraunhofer, Technical University Munich, its Venture Lab, VCs, or roles of Ludwig-Maximilians-University and Max-Planck-Institutes. Some shortcomings of the biotech ecosystem, a deep look at BioM’s revenues, and its track record. Includes an interview with Ralf Huss, BioM Managing Director since 2023. (updated November 2024)Reading time: 29 min
Read Now: |
B2Bioworld offers you background information
Gauging political claims and educational objectives for a digital civil society. Extended Book Review. Free access.
Analysis and in-depth interview with GAIA-X aisbl executives
The state's Deputy Prime Minister responsible for Economy outlines strategy and plans. What about preparedness?
Reinhard Pfeiffer, CEO München Messe on balancing geopolitical risks in Rssia, China, South Afica and elsewhere. Perspectives in the Americas
Walter Kolch on setting the Irish Institute apart from other System Biology in the world